Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Longeveron Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners, indicating that each application is receiving an independent review. Furthermore, the portfolio involves 2 distinct art units, which shows that the company's patent activity is spread across different technical departments at the USPTO. This lack of consolidation suggests a broader technical scope for the 2 pending matters. The presence of 2 distinct art units requires a strategy that accounts for different departmental standards.
The busiest examiner for this portfolio is ABEYRATNE-PERERA, HASHANTHI KOMITIGE, who is responsible for 1 pending office action. Because the busiest examiner pending count is 1, the total of 2 pending office actions is split between the 2 distinct examiners. For the legal team, this means managing 2 separate prosecution tracks in 2 different art units simultaneously. The diversity in both 2 distinct examiners and 2 distinct art units requires a versatile approach to address different examination styles. Practitioners must coordinate across these separate channels to advance the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1 | 0.0% | +0.0% |
| TICHY, JENNIFER M.H. | 1 | 64.9% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044092 | Treatment of Alzheimer's Disease with Allogeneic Mesenchymal Stem Cells | TICHY, JENNIFER M.H. | 71d overdue |
| 18682949 | TREATMENT OF AGING FRAILTY COMPRISING ADMINISTERING BONE MARROW DERIVED MESENCHYMAL STEM CELLS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044092 | Treatment of Alzheimer's Disease with Allogeneic Mesenchymal Stem Cells | TICHY, JENNIFER M.H. | 71d overdue |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682949 | TREATMENT OF AGING FRAILTY COMPRISING ADMINISTERING BONE MARROW DERIVED MESENCHYMAL STEM CELLS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1632 | §102§112 | Final Rejection | — | Pending | Feb 12, 2024 |
| 18044092 | Treatment of Alzheimer's Disease with Allogeneic Mesenchymal Stem Cells | TICHY, JENNIFER M.H. | 1653 | §102§103§112 | Non-Final OA | 71d overdue | Pending | Mar 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial